Guggenheim Reiterates “Buy” Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports. Several other research analysts have also commented on ORIC. JPMorgan Chase & Co. lifted their price objective on shares of ORIC Pharmaceuticals from $19.00 to $21.00 […]
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a research report issued to clients and investors on Monday,Benzinga reports. Several other research analysts have also commented on ORIC. JPMorgan Chase & Co. lifted their price objective on shares of ORIC Pharmaceuticals from $19.00 to $21.00 […]
